Pain management providers are operating in one of the most dynamic regulatory environments in recent years. From landmark FDA approvals to sweeping changes in how controlled substances can be prescribed via telehealth, the rules governing acute and chronic pain care are shifting rapidly in 2026.
A New Era for Non-Opioid Treatment
For the first time in more than two decades, a new class of pain medicine has earned FDA approval. Journavx (suzetrigine), approved in early 2025, represents a significant departure from traditional opioid-based therapies and has already begun reshaping how clinicians think about acute pain management. Alongside this development, the NOPAIN Act is expanding Medicare reimbursement for non-opioid alternatives in ambulatory surgery centers and hospital outpatient departments, removing financial barriers that long favored opioids by default. The implications for perioperative protocols, formulary decisions, and patient counseling are substantial.
CDC Guidelines, Federal Standards, and the Compliance Gap
The CDC has spent a decade refining its opioid prescribing guidance, and its 2022 update made clear that clinical recommendations should never be treated as hard mandates. Yet the gap between what guidelines say and how payers, health systems, and state regulators apply them remains a source of real risk for prescribers. That gap has real consequences, as do the federal safety standards now actively enforced across Medicare Part D plans. How providers document their clinical decision-making is no longer just good practice, it is a line of defense.
Telehealth, Training, and Technology
The COVID-era telehealth flexibilities that allowed clinicians to prescribe controlled substances without a prior in-person visit have been extended through the end of 2026, but permanent rules are still pending. The DEA has proposed a special registration framework that would create new pathways, and new obligations, for providers prescribing Schedule II through V substances via telehealth. At the same time, the MATE Act now requires all DEA-registered practitioners to complete training on opioid and substance use disorders, and electronic prescribing compliance thresholds are being actively monitored by CMS. These are not hypothetical concerns. Providers who act now, before permanent rules take effect, will be in a far stronger position than those who wait.
What to Expect at PAINWeek 2026
To learn more about navigating these changes, join the presentation “Prescribing for Tomorrow” at PAINWeek 2026, taking place September 8-11 in Las Vegas. From state-level opioid prescribing limits to PDMP integration requirements to the FDA’s Opioid Analgesic REMS mail-back program, attendees will leave with a concrete compliance framework and a clearer picture of the year ahead. If you are a pain management provider, prescribing clinician, pharmacist, or healthcare administrator navigating this landscape, this is a session you will not want to miss.
About Frier Levitt
Frier Levitt is experienced in advising pain management providers, prescribing clinicians, and pharmacies on regulatory compliance. As the rules governing controlled substance prescribing, telehealth, and non-opioid reimbursement continue to evolve, Frier Levitt helps providers understand their obligations, document their decisions defensibly, and stay ahead of enforcement. Contact Frier Levitt to review your compliance program and ensure your practice is prepared for what comes next.
